Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Owen Mumford Announces Verified Science-based Targets & Plans for Net zero

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, has announced its emissions reduction targets through the Science Based Targets initiative (SBTi). The company has set a target to achieve net zero by 2045 (to mirror the UK NHS target) in alignment with the recommendations of the 2015 Paris Agreement.

Using science-based targets, companies can determine how much and how quickly they need to reduce their greenhouse gas (GHG) emissions to prevent the worst effects of climate change. The Science Based Targets initiative (SBTi) sets science-based emissions reduction targets in line with climate science, supporting companies as they mobilise ambitious climate action efforts in the private sector. Over 2,000 companies worldwide have already set their targets.

As part of its sustainability action plan, the company has joined the Business Ambition for 1.5°c commitment and is one of the first 1000 global businesses to sign up. Launched in 2019, the initiative asks members to pledge to achieve net zero emissions by the latest 2050 following the United Nations Intergovernmental Panel on Climate Change (IPCC) warning that an increase of 1.5°c in global temperature will have catastrophic effects.

By joining the commitment, Owen Mumford also joins the Race to Zero movement, a collaborative effort of leaders across the globe supporting efforts to achieve zero carbon recovery. Owen Mumford recently became one of the first medical device manufacturers in the world to achieve B Corp certification following the establishment of its sustainability programme in 2014 and formal commitment to the United Nation’s Sustainable Development Goals (SDGs). To formalise the pledge to reduce the environmental impact of its operations, Owen Mumford has now set a science-based target, with its base year as 2015. The company will establish a pathway in 2022, including milestones to mark the achievement of goals and measure its success. The focus will be on Scope 3 emissions, which covers factors such as purchased goods and services, business travel and waste disposal.

Jarl Severn, Ceo At Owen Mumford
Jarl Severn, Ceo At Owen Mumford

Jarl Severn, CEO at Owen Mumford said: “Owen Mumford has been an innovator of medical devices for decades, and we understand the importance of leading by example when it comes to the environment and our impact as a business. Setting a science-based target with the SBTi will hold us accountable and help us to reach our net zero target for 2045. We hope this commitment will inspire other businesses to implement their own sustainability targets and work towards the goal of a carbon neutral future.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy